Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
XLO Xilio Therapeutics
2.649
-0.071-2.61%
Post Mkt Price
2.6490.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Assets
Current assets
Cash, cash equivalents and short term investments
39.47% 139.14M 32.51% 159.41M -- 176.96M 929.49% 198.05M
-Cash and cash equivalents
39.47% 139.14M 32.51% 159.41M -- 176.96M 929.49% 198.05M
Prepaid assets
31.69% 3.17M 86.18% 3.6M -- 4.13M 241.28% 4.46M
Total current assets
34.80% 142.31M 30.84% 163.01M -- 181.09M 883.57% 202.52M
Non current assets
Net PPE
0.52% 13.24M -1.62% 13.23M -- 13.35M -0.58% 13.6M
-Gross PPE
10.81% 17.21M 8.47% 16.76M -- 16.47M 8.47% 16.31M
-Accumulated depreciation
-68.42% -3.96M -76.24% -3.53M -- -3.12M -99.41% -2.71M
Other non current assets
-6.16% 1.86M -5.03% 1.89M -- 1.91M -5.12% 1.95M
Total non current assets
-0.35% 15.1M -2.06% 15.12M -- 15.27M -1.17% 15.54M
Total assets
30.39% 157.41M 27.21% 178.13M -- 196.35M 500.44% 218.06M
Liabilities
Current liabilities
Payables
-52.64% 1.81M -83.23% 1.41M -- 2.32M -42.25% 3.14M
-accounts payable
-52.64% 1.81M -83.23% 1.41M -- 2.32M -42.25% 3.14M
Current accrued expenses
10.59% 9.06M 49.81% 12.09M -- 7.32M -36.27% 8.75M
Current debt and capital lease obligation
661.71% 5.89M -11.69% 4.19M -- 2.5M -72.35% 801K
-Current debt
-- 5M -16.68% 3.33M -- 1.67M -- --
-Current capital lease obligation
14.88% 888K 15.01% 858K -- 829K 42.02% 801K
Other current liabilities
0.00% 82K 0.00% 82K -- 82K 0.00% 82K
Current liabilities
30.85% 16.84M -16.59% 17.77M -- 12.23M -42.32% 12.78M
Non current liabilities
Long term debt and capital lease obligation
-28.58% 14.21M 0.34% 16.06M -- 17.91M 7.72% 19.74M
-Long term debt
-50.09% 4.78M 16.66% 6.39M -- 8.01M 29.90% 9.63M
-Long term capital lease obligation
-8.60% 9.43M -8.15% 9.66M -- 9.89M -7.34% 10.11M
Other non current liabilities
-95.80% 64K -92.79% 82K -- 100K -89.53% 118K
Total non current liabilities
-94.16% 14.27M -93.28% 16.14M -- 18.01M -79.63% 19.85M
Total liabilities
-87.90% 31.12M -87.02% 33.91M -- 30.23M -72.72% 32.63M
Shareholders'equity
Share capital
-- 3K -- 3K -- 3K -- 3K
-common stock
-- 3K -- 3K -- 3K -- 3K
-Preferred stock
-- 0 -- 0 -- 0 -- --
Retained earnings
-60.53% -226.64M -65.57% -206.85M -- -182.24M -89.09% -160.89M
Paid-in capital
7,361.67% 352.94M 9,584.58% 351.07M -- 348.36M 19,150.25% 346.31M
Total stockholders'equity
192.56% 126.3M 218.88% 144.22M -- 166.12M 322.64% 185.43M
Total equity
192.56% 126.3M 218.88% 144.22M -- 166.12M 322.64% 185.43M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
CEO: Dr. Rene Russo, Pharm.D.
Market: NASDAQ
Listing Date: 10/22/2021
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist